PAR : SIGHT.PA

GenSight Biologics S.A.

$0.0835 EUR

$0.0 (2.83%)

Volume
110.48K
Average Volume
523.82K
Market Capitalization
$13.61M
P/E Ratio
-1.03
Dividend Yield
0.00%
Price Target
Year High
$0.24
Year Low
$0.08
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$0.39
Company Overview

PAR

Laurence Rodriguez

Biotechnology

Healthcare

SIGHT.PA

13

FR

EUR

https://www.gensight-biologics.com

33 1 76 21 72 20

F4374K117

N/A

Liquidity Metrics

-0.52

0.39

0.39

0.19

0.00

Sales & Valuation

$1000

13610.50

-0.63

-1.49

-0.05

Profitability

-$0.0812

-$12.04M

-1203600.00%

-1204000.00%

42.20%

-145.78%

P/E Metrics

-1.03

-0.02

-0.02

Analyst Price Target & Rating

Sell

2/5

0 Analysts

%

Financial Health Scores

-13.60

2/9

-$7.69M

$8.26M

$33.2M

-$27.52M

Key Metrics (TTM)

No key metrics data available.

Company Executives
Name Title
Julio Benedicto Senior Vice President of Strategy & Operations
Scott Jeffers Chief Technical Officer
Jose-Alain Sahel Scientific Founder, Vice Chairman of Scientific Advisory Board & Director
Magali Taiël Chief Medical Officer
Serge Picaud Scientific Founder & Member of Scientific Advisory Board
Botond Roska Scientific Founder & Chairman of Scientific Advisory Board
Fang Li Chief Regulatory & Quality Officer
Barrett Katz Consultant
Laurence Rodriguez Chief Executive Officer & Director
Marion Ghibaudo Chief Technical Officer of Medical Device
Jan Eryk Umiastowski Chief Financial Officer
Poll Results

No votes yet today — be the first to share your view!

About GenSight Biologics S.A. (PAR:SIGHT.PA) Stock

GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry ... age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.

Frequently Asked Questions

What is the current GenSight Biologics S.A. (SIGHT.PA) stock price?

GenSight Biologics S.A.(PAR:SIGHT.PA) stock price is $0.0835 in the last trading session. During the trading session, SIGHT.PA stock reached the peak price of $0.239 while $0.0752 was the lowest point it dropped to. The percentage change in SIGHT.PA stock occurred in the recent session was 2.83% while the dollar amount for the price change in SIGHT.PA stock was $0.0.

SIGHT.PA's industry and sector of operation?

The PAR listed SIGHT.PA is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of SIGHT.PA?

Julio Benedicto | Senior Vice President of Strategy & Operations
Scott Jeffers | Chief Technical Officer
Jose-Alain Sahel | Scientific Founder, Vice Chairman of Scientific Advisory Board & Director
Magali Taiël | Chief Medical Officer
Serge Picaud | Scientific Founder & Member of Scientific Advisory Board

How many employees does SIGHT.PA have?

Number of SIGHT.PA employees currently stands at 13. SIGHT.PA operates from 74, rue du Faubourg Saint-Antoine, Paris, IF 75012, FR.

Link for SIGHT.PA official website?

Official Website of SIGHT.PA is: https://www.gensight-biologics.com

How do I contact SIGHT.PA?

SIGHT.PA could be contacted at phone #33 1 76 21 72 20 and can also be accessed through its website. SIGHT.PA operates from 74, rue du Faubourg Saint-Antoine, Paris, IF 75012, FR.

How many shares of SIGHT.PA are traded daily?

The average number of SIGHT.PA shares traded daily for last 3 months was 523.82K.

What is the market cap of SIGHT.PA currently?

The market value of SIGHT.PA currently stands at $13.61M with its latest stock price at $0.0835